1 INTRODUCTION
1.1 MARKET SEGMENTATION

2 RESEARCH METHODOLOGY
2.1 ECOSYSTEM OF GLOBAL CAR T-CELL THERAPY MARKET
2.2 TOP-DOWN APPROACH
2.3 BOTTOM-UP APPROACH
2.4 ASSUMPTIONS

3 EXECUTIVE SUMMARY
3.1 GLOBAL CAR T-CELL THERAPY MARKET SNAPSHOT

4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 KEY TREND ANALYSIS
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS

5 GLOBAL CAR T-CELL THERAPY MARKET, BY TARGETED ANTIGEN
5.1 OVERVIEW
5.2 HER1
5.3 HER2
5.4 CD19
5.5 CD20
5.6 CD22
5.7 CD30
5.8 CD33
5.9 GD2
5.10 MESO AND
5.11 EGFRVIII

6 GLOBAL CAR T-CELL THERAPY MARKET, BY TREATMENT
6.1 OVERVIEW
6.2 NON-HODGKIN LYMPHOMA (NHL)
6.3 CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
6.4 ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
6.5 MULTIPLE MYELOMA
6.6 ACUTE MYELOID LEUKEMIA (AML)
6.7 BREAST CANCER
6.8 PANCREATIC CANCER
6.9 NEUROBLASTOMA (NB)
6.10 COLON CANCER AND
6.11 HEPATOCELLULAR CARCINOMA (HCC)

7 GLOBAL CAR T-CELL THERAPY MARKET, BY GEOGRAPHY
7.1 NORTH AMERICA
7.1.1 MARKET DYNAMICS
7.1.2 U.S.
7.1.3 CANADA
7.1.4 MEXICO
7.2 EUROPE
7.2.1 MARKET DYNAMICS
7.2.2 U.K.
7.2.3 ITALY
7.2.4 FRANCE
7.2.5 GERMANY
7.2.6 RUSSIA
7.2.7 SPAIN
7.2.8 REST OF EUROPE
7.3 ASIA PACIFIC
7.3.1 MARKET DYNAMICS
7.3.2 INDIA
7.3.3 CHINA
7.3.4 JAPAN
7.3.5 AUSTRALIA
7.3.6 REST OF ASIA PACIFIC
7.4 MIDDLE EAST AND AFRICA
7.4.1 MARKET DYNAMICS
7.4.2 GCC
7.4.3 SOUTH AFRICA
7.4.4 REST OF MIDDLE EAST AND AFRICA
7.5 LATIN AMERICA
7.5.1 MARKET DYNAMICS
7.5.2 BRAZIL
7.5.3 REST OF LATIN AMERICA

8 COMPETATIVE LANDSCAPE
8.1 OVERVIEW
8.2 MARKET SHARE ANALYSIS
8.3 PATENT ANALYSIS

9 GLOBAL CAR T-CELL THERAPY MARKET, BY COMPANY
9.1 INTRODUCTION
9.2 NOVARTIS INTERNATIONAL AG
9.2.1 BUSINESS OVERVIEW
9.2.2 PRODUCT & SERVICES
9.2.3 KEY STRATEGY
9.2.4 RECENT DEVELOPMENTS
9.2.5 SWOT ANALYSIS
9.3 KITE PHARMA INC.
9.3.1 BUSINESS OVERVIEW
9.3.2 PRODUCT & SERVICES
9.3.3 KEY STRATEGY
9.3.4 RECENT DEVELOPMENTS
9.3.5 SWOT ANALYSIS
9.4 JUNO THERAPEUTICS
9.4.1 BUSINESS OVERVIEW
9.4.2 PRODUCT & SERVICES
9.4.3 KEY STRATEGY
9.4.4 RECENT DEVELOPMENTS
9.4.5 SWOT ANALYSIS
9.5 CELLECTIS
9.5.1 BUSINESS OVERVIEW
9.5.2 PRODUCT & SERVICES
9.5.3 KEY STRATEGY
9.5.4 RECENT DEVELOPMENTS
9.5.5 SWOT ANALYSIS
9.6 BELLICUM PHARMACEUTICALS INC. AND
9.6.1 BUSINESS OVERVIEW
9.6.2 PRODUCT & SERVICES
9.6.3 KEY STRATEGY
9.6.4 RECENT DEVELOPMENTS
9.6.5 SWOT ANALYSIS
9.7 CELGENE CORPORATION
9.7.1 BUSINESS OVERVIEW
9.7.2 PRODUCT & SERVICES
9.7.3 KEY STRATEGY
9.7.4 RECENT DEVELOPMENTS
9.7.5 SWOT ANALYSIS